NASDAQ:ISO IsoPlexis (ISO) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.76▼$0.7650-Day Range$0.74▼$1.1352-Week Range$0.60▼$5.10VolumeN/AAverage Volume68,375 shsMarket Capitalization$30.28 millionP/E RatioN/ADividend YieldN/APrice Target$1.60 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About IsoPlexis (NASDAQ:ISO) StockIsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.Read More Receive ISO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IsoPlexis and its competitors with MarketBeat's FREE daily newsletter. Email Address ISO Stock News HeadlinesMay 16, 2023 | marketwatch.com10-Q: PHENOMEX INC.May 12, 2023 | finanznachrichten.dePhenomeX Reports First Quarter 2023 Financial ResultsJune 10, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Software" to Revolutionize WarfareThis breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>May 5, 2023 | marketwatch.comSingle Cell Proteomics System Market Insights, Forecast to 2029 Market Size 2023-2031 Industrial Regions by Absolute Reports | with [90 Pages]May 3, 2023 | marketwatch.comSingle Cell Proteomics Analysis System Market Insights, Forecast to 2029 Market Size and volume sale report 2023April 14, 2023 | marketwatch.comTabula Rasa HealthCare Removes Interim Tag, Names Brian Adams CEOApril 13, 2023 | americanbankingnews.comContrasting IsoPlexis (ISO) and Its CompetitorsApril 11, 2023 | americanbankingnews.comIsoPlexis (ISO) & Its Competitors Critical ContrastJune 10, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Software" to Revolutionize WarfareThis breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>April 8, 2023 | americanbankingnews.comIsoPlexis (ISO) and Its Peers Head to Head ReviewApril 2, 2023 | americanbankingnews.comCritical Survey: IsoPlexis (ISO) vs. Its PeersMarch 26, 2023 | americanbankingnews.comContrasting IsoPlexis (ISO) and The CompetitionMarch 23, 2023 | americanbankingnews.comAnalyzing IsoPlexis (ISO) and The CompetitionMarch 23, 2023 | americanbankingnews.comIsoPlexis (ISO) and Its Competitors Head-To-Head AnalysisMarch 21, 2023 | finance.yahoo.comPhenomeX Strengthens Commercial Leadership TeamMarch 21, 2023 | americanbankingnews.comContrasting Harvard Bioscience (NASDAQ:HBIO) and IsoPlexis (NASDAQ:ISO)February 18, 2023 | finance.yahoo.comIsoPlexis Corporation (ISO) Stock Historical Prices & Data - Yahoo FinanceFebruary 9, 2023 | finance.yahoo.comIsoPlexis Corporation's (NASDAQ:ISO) recent US$6.3m market cap decline means a loss of US$65k for insiders who bought this yearFebruary 4, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Investigates IsoPlexis CorporationJanuary 15, 2023 | finanznachrichten.deIsoPlexis Corporation: Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology CompanyJanuary 12, 2023 | benzinga.comIsoPlexis Granted U.S. Patent Titled 'METHODS OF USING NUCLEOTIDE ANALOGUES'January 12, 2023 | msn.comIsoPlexis expects FY22 revenue to be below consensusJanuary 12, 2023 | finance.yahoo.comIsoPlexis Reports Preliminary Full Year 2022 RevenueJanuary 10, 2023 | msn.comBerkeley Lights' Preliminary 2022 Results Deficient, Analysts Say All Eyes On IsoPlexis ExecutionJanuary 5, 2023 | msn.comMorgan Stanley Maintains Equal-Weight Rating for IsoPlexis: Here's What You Need To KnowDecember 23, 2022 | barrons.comThinking about buying stock in Mullen Automotive, Cleveland-Cliffs, CarMax, IsoPlexis, or Teva Pharmaceutical?December 23, 2022 | markets.businessinsider.comAnalysts Conflicted on These Technology Names: Workday (WDAY) and IsoPlexis (ISO)See More Headlines ISO Company Calendar Last Earnings11/10/2021Today6/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ISO CUSIPN/A CIK1615055 Webisoplexis.com Phone203-208-4111FaxN/AEmployees459Year FoundedN/APrice Target and Rating Average Stock Price Forecast$1.60 High Stock Price Forecast$1.70 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+110.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,000,000.00 Net Margins-632.41% Pretax Margin-632.40% Return on Equity-127.86% Return on Assets-71.41% Debt Debt-to-Equity Ratio1.12 Current Ratio4.06 Quick Ratio2.50 Sales & Book Value Annual Sales$16.76 million Price / Sales1.81 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book0.73Miscellaneous Outstanding Shares39,760,000Free Float37,218,000Market Cap$30.28 million OptionableNot Optionable Beta1.32 Key ExecutivesMr. Sean Mackay (Age 40)Co-Founder, CEO, Pres & Director Comp: $635.55kMr. John R. Strahley CPA (Age 55)Chief Financial Officer Comp: $444.11kMr. Rong FanCo-Founder & Chairman of Scientific Advisory BoardMr. Jon ChenVP of Scientific Alliance Technology & Co-FounderMr. Anthony CatalanoSr. VP of OperationsMr. Rajesh T. KhakharVP of Fin. & Principal Accounting OfficerMs. Jing Zhou M.D. (Age 52)Ph.D., Chief Scientific Officer Mr. Richard W. Rew II (Age 54)Sr. VP, Gen. Counsel & Sec. Ms. Verna SiuSr. VP of Sales OperationsMs. Carrie CarterSr. VP of People OperationsMore ExecutivesKey CompetitorsTelesis BioNASDAQ:DNAYBerkeley LightsNASDAQ:BLIRapid Micro BiosystemsNASDAQ:RPIDPrecipioNASDAQ:PRPOTalis BiomedicalNASDAQ:TLISView All CompetitorsInsiders & InstitutionsCrystalline Management Inc.Bought 278,125 shares on 3/13/2023Ownership: 0.700%Nachum ShamirBought 10,253 shares on 8/30/2022Total: $19,378.17 ($1.89/share)Nachum ShamirBought 10,253 shares on 8/30/2022Total: $19,378.17 ($1.89/share)Sean MackayBought 15,000 shares on 8/25/2022Total: $29,850.00 ($1.99/share)John StrahleyBought 10,000 shares on 8/25/2022Total: $20,000.00 ($2.00/share)View All Insider TransactionsView All Institutional Transactions ISO Stock - Frequently Asked Questions Should I buy or sell IsoPlexis stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoPlexis in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ISO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ISO, but not buy additional shares or sell existing shares. View ISO analyst ratings or view top-rated stocks. What is IsoPlexis' stock price forecast for 2023? 2 Wall Street research analysts have issued 12-month price objectives for IsoPlexis' stock. Their ISO share price forecasts range from $1.50 to $1.70. On average, they expect the company's stock price to reach $1.60 in the next twelve months. This suggests a possible upside of 110.1% from the stock's current price. View analysts price targets for ISO or view top-rated stocks among Wall Street analysts. How were IsoPlexis' earnings last quarter? IsoPlexis Co. (NASDAQ:ISO) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($10.66) EPS for the quarter, missing analysts' consensus estimates of ($0.79) by $9.87. The company had revenue of $4.19 million for the quarter, compared to the consensus estimate of $3.79 million. IsoPlexis had a negative net margin of 632.41% and a negative trailing twelve-month return on equity of 127.86%. When did IsoPlexis IPO? (ISO) raised $125 million in an initial public offering on Friday, October 8th 2021. The company issued 8,333,000 shares at $14.00-$16.00 per share. What is IsoPlexis' stock symbol? IsoPlexis trades on the NASDAQ under the ticker symbol "ISO." What is IsoPlexis' stock price today? One share of ISO stock can currently be purchased for approximately $0.76. How much money does IsoPlexis make? IsoPlexis (NASDAQ:ISO) has a market capitalization of $30.28 million and generates $16.76 million in revenue each year. The company earns $-106,000,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis. How many employees does IsoPlexis have? The company employs 459 workers across the globe. How can I contact IsoPlexis? IsoPlexis' mailing address is 35 NE INDUSTRIAL ROAD, BRANFORD CT, 06405. The official website for the company is isoplexis.com. The company can be reached via phone at 203-208-4111 or via email at investors@isoplexis.com. This page (NASDAQ:ISO) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IsoPlexis Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.